www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

   

Healthcare sector woos investors

By Wang Xing (China Daily)
Updated: 2007-11-12 11:09

After a stormy anti-corruption campaign and regulatory personnel reshuffles last year, China's healthcare industry seems to have emerged from the dark clouds to become a hot focus of investors from both home and abroad.

"China's healthcare spending will grow dramatically with continued GDP growth," says Norman Chen, partner from venture capital firm FAV.

"By 2010, China will be the world's sixth-largest healthcare market with industry turnover surpassing US$27 billion. Obviously, it is not about whether we should put our money in this area but time to think of which part of the sector we should invest in."

China's rapid economic growth, which has averaged 8 to 9 percent annually since 1978, is enabling ordinary Chinese to spend more on healthcare.

As well, the unprecedented demographic transition brought by decreasing birth rates and an increasingly elderly population has also resulted in a boom in the number of hospitals, pharmaceutical companies and medical equipment manufacturers in the country.

According to domestic research firm ChinaVenture, venture capital investment in China's healthcare market reached US$31 million in the third quarter of this year, an increase of nearly 200 percent over US$11 million in the second quarter.

The flow of capital into Chinese healthcare companies has also resulted in an unprecedented number of initial public offerings (IPOs) by healthcare companies.

In the first 10 months of this year, seven Chinese healthcare companies were listed in overseas stock markets, a significant jump from four listings a year earlier, according to Zero2IPO, a local researcher on the venture capital market.

Li Ying, secretary of the China Association for Medical Devices Industry, says "Chinese pharmaceutical companies and medical equipment companies are striving for expansion, but often face bottlenecks in investment, research and development abilities and management experience."

She notes that the involvement of venture capitalists, which often bring with them expertise in management, financing and marketing, can help Chinese healthcare companies to grow in line with the country's booming market.

Although optimistic about China's healthcare companies, investors say that risk certainly exists, especially in pharmaceutical companies.

"We are especially wary when evaluating investment in new drug research," says Zhang Suyang, partner from IDG VC.

"Drug research, unlike healthcare services and medical devices, is a highly professional area that only a limited number of experts fully understand. It is a challenge for fund managers like us."

Zhang's remark was echoed by a researcher from Merrill Lynch.

"According to our observations, there are six Chinese pharmaceuticalcompanies listed in the United States, but their price-to-earnings (P/E) ratios are much lower than companies providing medical equipment and services in China," says the researcher who declined to be named.

He says it is partly due to the perception by investors in the US that the patent power of the Chinese pharmaceutical companies is not strong enough to sustain growth of new drugs in the international market, which means they are more likely to be involved in legal issues in countries like the United States or in Europe, where patent laws are strict.

A P/E ratio is the relationship of a company's share price to its earnings used to evaluate its value for money.

Norman from FAV contents investment in Chinese pharmaceutical companies should be "extremely careful", but adds Chinese companies have its some advantages in new drug research.

"China has a more efficient new drug approval system and is more cost-effective in undertaking experiments and recruiting volunteers, which is a huge plus," he says.

In the US, it often takes 10 to 15 years and US$600 million before a new drug is approved. But in China, it needs an average of five years and 50 million yuan, according to industry estimates.

"Whatever challenges or opportunities, China's healthcare market is just in its inception," says Zhang from IDG VC.

"It's like the time of gold rush - many people who panned for gold failed, but people who sold them drinking water made the wealth," he says.

"I think in China we may first need to fund those who sell the water."


(For more biz stories, please visit Industry Updates)



Related Stories  
主站蜘蛛池模板: 欧美精品国产制服第一页 | 精品亚洲成a人在线观看 | 一区二区成人国产精品 | 精品一区二区三区免费视频 | 成人久久18免费网站入口 | 1204国产成人精品视频 | 亚洲精品久久久久影 | 中文字幕精品一区二区精品 | 精品国产成人三级在线观看 | 亚洲一区在线观看视频 | wwwxxx黄色| 视频二区 中文字幕 欧美 | 成人性动漫高清免费观看网址 | 国产成人3p视频免费观看 | 国模午夜写真福利视频在线 | 久久免费精品视频 | 成人性一级视频在线观看 | 成年人在线视频网站 | 国产成人盗拍精品免费视频 | 久久精品免看国产 | 久久99国产精品久久99果冻传媒 | 精品视频在线一区 | 亚州中文 | 最近中文字幕精彩视频 | 女人张开腿让男人桶视频 | 国产成人精品一区二区视频 | 成人国产精品高清在线观看 | 在线观看亚洲免费视频 | 波多野在线视频 | 国产亚洲网站 | 欧美成人午夜影院 | 草久在线播放 | 日本高清免费视频色www | 一级待一黄aaa大片在线还看 | 国内高清久久久久久久久 | 九九九九九九精品免费 | 国产一区二区不卡 | 特级做a爰片毛片免费看 | 一本久道在线 | 久久久久亚洲精品中文字幕 | 真人真实毛片免费观看 |